PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy.
Schalkwijk
Casper G
CG
Stehouwer
Coen D A
CD
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D007210:Indoleacetic Acids / Q000494:pharmacology; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*
D019440:Anti-Obesity Agents; D007210:Indoleacetic Acids; D017395:Plasminogen Activator Inhibitor 1; C488103:tiplaxtinin